Espoo, Finland, August 20, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Company’s 1H 2026 report. The full report is attached to this release and is also available on the Company’s website: www.herantis.com.
Read more at globenewswire.comHerantis Pharma releases 1H 2026 report today
Barchart·08/20/2026 06:00:00
語音播報
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.